In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations.
This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.
Shelburne
Samuel A
SA
Section of Infectious Diseases (111G), Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd., Houston, TX 77030-4211, USA.
Musher
Daniel M
DM
Hulten
Kristina
K
Ceasar
Heather
H
Lu
Michael Y
MY
Bhaila
Imran
I
Hamill
Richard J
RJ
D017714:Community-Acquired Infections / Q000382:microbiology*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D016106:Methicillin Resistance; D012293:Rifampin / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology
D005839:Gentamicins; D014640:Vancomycin; D012293:Rifampin